A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-17

Study Completion Date

2022-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Ringer Perfusion Balloon Catheter (Ringer PTCA)

NCT04862689

Coronary Stenosis

COMPLETED NA

DCB Compared Stenting in Popliteal Lesions

NCT03739580

Popliteal Stenosis Popliteal Artery Occlusion Diabetes

UNKNOWN NA

Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease

NCT05509296

Coronary Stenosis Coronary Artery Stenosis In-stent Restenosis

COMPLETED NA

A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW

NCT02962232

Peripheral Artery Disease

UNKNOWN NA

Constrained Balloon Combined With Drug-coated Balloon Angioplasty for Femoropopliteal Lesion

NCT05894460

Peripheral Arterial Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigation is a prospective, multi-center, single arm clinical study. The study will be conducted in up to 15 investigational sites in the U.S. This study will enroll and treat 200 subjects, including a minimum of 30 subjects with in-stent restenosis (ISR).

The population for this study is subjects with stenotic coronary artery disease who are suitable candidates for PTCA.

After screening for initial inclusion and exclusion criteria, eligible subjects will be asked to participate in the study by signing a consent form. Following consent, subjects will undergo a baseline visit where additional eligibility criteria will be assessed. An angiogram will be completed to assess for angiographic eligibility. If a non-target lesion is identified, it must be treated successfully prior to target lesion treatment. Once treatment of the target lesion(s) has been attempted, the subject will be considered enrolled in the study.

Subjects will be followed through hospital discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Stenosis Coronary Artery Stenosis In-stent Restenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

A prospective, multi-center, single arm clinical study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lacrosse NSE ALPHA percutaneous coronary intervention (PCI)

Percutaneous coronary intervention (PCI) in which at least one Lacrosse NSE ALPHA device is used.

Group Type EXPERIMENTAL

Lacrosse NSE ALPHA coronary dilatation catheter

Intervention Type DEVICE

The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lacrosse NSE ALPHA coronary dilatation catheter

The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 years or older.
2. Willing to provide written informed consent and written HIPAA authorization prior to initiation of study-related procedures.
3. Agree to not participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.
4. Clinical evidence of ischemic heart disease, stable/unstable angina, or silent ischemia.
5. Acceptable candidate for PCI and emergency coronary artery bypass grafting and is planned for possible PTCA and/or stent placement.

6. De novo or restenotic lesion(s) in native coronary arteries, including in-stent restenosis.
7. A maximum of two lesions, including at least one target lesion, in single or double vessel coronary artery disease.

1. If two target lesions are defined, then no non-target lesions can be treated.
2. If a single target lesion is defined, then a single non-target lesion may be treated, but if so, it must be located in a different coronary artery from the target lesion.
8. Target lesion(s) must have a reference vessel diameter between 2.0 mm and 4.0 mm by visual estimation.
9. Target lesion(s) must have a diameter stenosis of (a) ≥70% by visual estimation or (b) \>50% by visual estimation and a fractional flow reserve (FFR) of \<0.80 or resting full-cycle ratio (RFR) or instantaneous wave-free ratio (iFR) \<0.9.
10. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion; must not, in the opinion of the investigator, impact the conduct or completion of the index procedure; and must be deemed a clinical angiographic success as visually assessed by the investigator.

EXLUSION CRITERIA

Exclusion Criteria

1. Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, a clopidogrel non-responder, or sensitivity to contrast media that cannot be adequately pre-medicated or replaced with a clinically suitable alternative.
2. Known diagnosis of type I myocardial infarction (resulting from primary reduction of flow from a culprit lesion likely to have a thrombotic component) within 7 days prior to the index procedure.
3. Known pregnancy or is nursing. Women of child-bearing potential should have a documented negative pregnancy test within 7 days prior to index procedure.
4. Planned target lesion treatment with atherectomy (rotational, orbital or laser), cutting balloon, thrombectomy, lithotripsy or an unapproved device during the index procedure.
5. Serum creatinine \>2.0 mg/dl within 7 days prior to the index procedure.
6. Cerebrovascular accident within 6 months prior to the index procedure.
7. Active peptic ulcer or active gastrointestinal bleeding within 6 months prior to the index procedure.
8. Left ventricular ejection fraction \<30% based on most recent measurement within a year of the index procedure (if LVEF is not available in the medical records, it may be obtained at the time of the index procedure, prior to enrollment).
9. Target lesion located within a bypass graft (venous or arterial) or graft anastomosis.
10. Previous percutaneous intervention, within 9 months before the study procedure, on lesions in a target vessel (including side branches) that are located within 10 mm from the current target lesion(s).
11. Target lesion(s) with complete total occlusion defined as the complete obstruction of a native coronary artery, exhibiting TIMI 0 or TIMI 1 flow, with an occlusion duration of at least 3 months.
12. Unstable hemodynamics or shock.
13. Other medical condition which might, in the opinion of the investigator, put the patient at risk or confound the results of the study.

14. Target lesion(s) longer than 32 mm by visual estimation.
15. Extreme angulation (90º or greater) within 5 mm of the target lesion.
16. Target lesion(s) demonstrating flow limiting dissection (NHLBI Grade C or higher) prior to deployment of the Lacrosse NSE ALPHA.
17. Unprotected left main coronary artery disease (\>50% diameter stenosis).
18. Coronary artery spasm of the target vessel in the absence of a significant stenosis.
19. Target lesion(s) with angiographic presence of probable or definite thrombus.
20. Target lesion(s) involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch \>2.0 mm in diameter.
21. Target lesion(s) located in bifurcation beyond stent struts.
22. Target lesion(s) located distal to an implanted stent.
23. Target lesion(s) with stent damage.
24. Non-target lesion that meets any of the following criteria:

* Located within a bypass graft (venous or arterial)
* Located in an unprotected left main coronary artery
* A CTO
* Involves a bifurcation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No